Stock Analysis
Caris Life Sciences, Inc. (CAI) Stock Analysis
Caris Life Sciences, Inc. (CAI) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Caris Life Sciences, Inc. (CAI) currently has an AIQ Score of 70/100, indicating a bullish setup. Momentum is the strongest factor at 85/100. Risk is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
CAI at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $23.04 |
| AIQ Score | 70/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $6.54B |
| P/E Ratio (TTM) | 68.59 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $0.05 |
| Revenue (Q3 FY2026) | $275.36M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.85 |
| Volume | 3.02M |
| 52-week range | $14.19-$36.50 |
| RSI 14 | 30.87 |
| 50-Day SMA | $29.39 |
| 200-Day SMA | $21.63 |
| Analyst Price Target | $38.00 |
| Next Earnings | Feb 25, 2027 |
CAICaris Life Sciences, Inc.
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum85
- Value68
- Quality71
- Risk resilience36
- Sentiment—
CAI Stock Analysis Summary
Caris Life Sciences, Inc. (CAI) currently has an AIQ Score of 70/100, indicating a bullish setup. Momentum is the strongest factor at 85/100. Risk resilience is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, CAI has AIQ Score of 70/100 with Momentum base of 85/100 and fading Risk resilience at 36/100. Wait for component alignment before adding exposure.
Momentum (85/100) leads while Risk resilience (36/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -3.84% stock move · CAI classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is CAI Bullish or Bearish Right Now?
CAI currently has a bullish overall setup. Momentum is the strongest factor at 85/100, while Risk Resilience is weakest at 36/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 71/100.
- - Momentum is constructive at 85/100.
- - Analyst target implies +64.93% upside from the latest quote.
- - Risk Resilience is weak at 36/100.
- - Technical consensus has more sell votes than buy votes (35 vs 7).
Current Consensus
CAI's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 4 neutral, and 35 sell votes. CAI's 14-day RSI is 30.87, which places the stock in a weaker momentum range. CAI's beta is 1.85, indicating greater market sensitivity than the broad market.
What Changed in CAI?
The largest recent change in CAI is Momentum moving down by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the CAI Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
CAI Decision Framework
Public evidence layers, setup checks, and risk context for Caris Life Sciences, Inc..
Caris Life Sciences, Inc. (CAI) Stock Analysis
Caris Life Sciences, Inc. has an AIQ Score of 70/100 in a Bullish regime. Momentum is strongest at 85/100. Beta is 1.85, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | CAI is in a Bullish AIQ regime with score 70/100. |
| Signal Conflict | The primary conflict is that momentum leads at 85/100 while risk lags at 36/100. |
| Factor Evidence | Momentum 85/100 · Value 68/100 · Quality 71/100 · Risk 36/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 85/100.
Momentum is 85/100 and RSI (14) is 30.9.
CAI is in a Bullish regime at 70/100.
Risk factor is 36/100 with beta 1.85 and annual volatility 69.82%.
Current conflict: momentum leads at 85/100 while risk lags at 36/100.
CAI Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
CAI Fundamentals
CAI valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
CAI Technical Analysis
CAI technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
CAI Stock Catalysts
Track CAI earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
CAI Dividend Analysis
CAI dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
CAI Financial Data
CAI revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
CAI Risk Analysis
CAI volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
CAI Stock News
CAI stock news, market tone, recent headlines, and catalyst context.
CAI vs Biotechnology Peers
Current peer cohort: CAI · CAPR · CELC · CGON · CLDX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| CAI Current stock | 70/100 | 68/100 | 85/100 | 36/100 | 0.22 | 69.82% | Current |
| CAPR Capricor Therapeutics, Inc. | 38/100 | — | 45/100 | 16/100 | 0.93 | 395.16% | CAI vs CAPR |
| CELC Celcuity Inc. | 41/100 | — | 24/100 | 34/100 | -0.19 | 63.58% | CAI vs CELC |
| CGON CG Oncology Inc. | 59/100 | — | 71/100 | 59/100 | 1.38 | 58.41% | CAI vs CGON |
| CLDX Celldex Therapeutics, Inc. | 43/100 | — | 48/100 | 55/100 | 0.55 | 52.44% | CAI vs CLDX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for CAI: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching CAI
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for CAI
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
CAI Stock FAQ
What is CAI stock price today?
Caris Life Sciences, Inc.'s current stock price is $23.04. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is CAI bullish or bearish right now?
CAI's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is CAI's market cap?
CAI's market cap is $6.54B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is CAI's current P/E ratio?
CAI's current P/E ratio is 68.59 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is CAI's RSI?
CAI's 14-day RSI is 30.87 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is CAI above its 50-day and 200-day moving averages?
CAI is -21.60% from its 50-day SMA and 6.51% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is CAI's next earnings date?
CAI's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does CAI pay a dividend?
CAI's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.